Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Similar Outcome with Early Reduced Intensity Conditioning (RIC) Allogeneic Transplant to Autologous-Non-Myeloablative Allogeneic (Auto-Allo) Transplant in Patients with Multiple Myeloma.

Sahebi Firoozeh, MD, Jeffery R. Schriber, M.D., Ricardo Spielberger, M.D., Ji-Lian Cai, M.D., Neil Martin Kogut, M.D., Peter M. Falk, M.D., Pablo Miguel Parker, M.D., Amrita Krishnan, M.D., Leslie Popplewell, M.D., Chatchada Karanes, M.D., Dajun Qian, PhD., Stephen J. Forman, M.D., George Somlo, M.D.

Blood (2007) 110 (11): 3030.

https://doi.org/10.1182/blood.V110.11.3030.3030

Published: 2007

Journal Articles

Peripheral Hematopoietic Stem Cell Mobilization and Collection Efficacy Is Not an Independent Prognostic Factor for Autologous Stem Cell Transplantation.

Shirong Wang, MD, Auayporn P. Nademanee, MD, Dajun Qian, PhD, Andrew Dagis, PhD, Hyun-Soon Park, RN, Joy Fridey, MD, Eileen Patricia Smith, MD, David S. Snyder, MD, Ravi Bhatia, MD, Peter M. Falk, MD, Candace Kay, MT, Young Sun Kim, MD, Neil Martin Kogut, MD, Joycelynne Palmer, PhD, Joseph Rosenthal, MD, George Somlo, MD, Anthony Selwyn Stein, MD, Shan Yuan, MD, Stephen J. Forman, MD

Blood (2006) 108 (11): 5434.

https://doi.org/10.1182/blood.V108.11.5434.5434

Published: 2006

Journal Articles

Tandem Cycle High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Maintenance Interferon Alpha-2 (IF) with or without Thalidomide (Thal) Is Associated with High Complete and Very Good Partial Response Rates, Improved Progression-Free, and Overall Survival.

George Somlo, MD, Dajun Qian, PhD, Firoozeh Sahebi, MD, Neil Martin Kogut, MD, Roberto Rodriguez, MD, Pablo Miguel Parker, MD, Leslie Popplewell, MD, Amrita Krishnan, MD, Joycelynne Palmer, PhD, Anthony Selwyn Stein, MD, Ricardo Spielberger, MD, Jeffrey Schriber, MD, Joseph Alvarnas, MD, Warren Chow, MD, Auayporn Nademanee, MD, Jasmine M. Zain, MD, Margaret R. O’Donnell, MD, Stephen J. Forman, MD

Blood (2006) 108 (11): 3089.

https://doi.org/10.1182/blood.V108.11.3089.3089

Published: 2006

Journal Articles

High-Dose Therapy (HDT) with Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Poor Prognosis Ewing Family Tumors (EFT).

Ellen Bolotin, MD, PhD, Marianna Shakhnovits, M.P.H., PhD, Laurence Cooper, MD, PhD, Dajun Qian, PhD, Debbie Hitt, R.N., Robert Sweetman, MD, Judith Sato, MD, James Miser, MD, Stephen Forman, MD, Joseph Rosenthal, MD

Blood (2005) 106 (11): 5500.

https://doi.org/10.1182/blood.V106.11.5500.5500

Published: 2005

Journal Articles

The Use of Reduced Intensity Allogeneic Stem Cell Transplantation (alloSCT) for Recurrence after Autologous Stem Cell Transplantation (ASCT) in Hodgkin’s Disease (HD).

Amrita Y. Krishnan, MD, Auayporn Nademanee, MD, Henry C. Fung, MD, Leslie Popplewell, MD, Roberto Rodriguez, MD, Zaid Al Kadhimi, MD, Mark Kirschbaum, MD, Neil Kogut, MD, Andrew Raubitschek, MD, Jeffrey Schriber, MD, Jasmine Zain, MD, Eileen Smith, MD, Nigel Cheng, Dajun Qian, PhD, Arturo Molina, MD, Stephen J. Forman, MD

Blood (2004) 104 (11): 5115.

https://doi.org/10.1182/blood.V104.11.5115.5115

Published: 2004

NARROW

Similar Outcome with Early Reduced Intensity Conditioning (RIC) Allogeneic Transplant to Autologous-Non-Myeloablative Allogeneic (Auto-Allo) Transplant in Patients with Multiple Myeloma.

Peripheral Hematopoietic Stem Cell Mobilization and Collection Efficacy Is Not an Independent Prognostic Factor for Autologous Stem Cell Transplantation.

Tandem Cycle High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Maintenance Interferon Alpha-2 (IF) with or without Thalidomide (Thal) Is Associated with High Complete and Very Good Partial Response Rates, Improved Progression-Free, and Overall Survival.

High-Dose Therapy (HDT) with Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Poor Prognosis Ewing Family Tumors (EFT).

The Use of Reduced Intensity Allogeneic Stem Cell Transplantation (alloSCT) for Recurrence after Autologous Stem Cell Transplantation (ASCT) in Hodgkin’s Disease (HD).

Email alerts

ASH Publications

American Society of Hematology

Similar Outcome with Early Reduced Intensity Conditioning (RIC) Allogeneic Transplant to Autologous-Non-Myeloablative Allogeneic (Auto-Allo) Transplant in Patients with Multiple Myeloma.

Peripheral Hematopoietic Stem Cell Mobilization and Collection Efficacy Is Not an Independent Prognostic Factor for Autologous Stem Cell Transplantation.

Tandem Cycle High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Maintenance Interferon Alpha-2 (IF) with or without Thalidomide (Thal) Is Associated with High Complete and Very Good Partial Response Rates, Improved Progression-Free, and Overall Survival.

High-Dose Therapy (HDT) with Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Poor Prognosis Ewing Family Tumors (EFT).

The Use of Reduced Intensity Allogeneic Stem Cell Transplantation (alloSCT) for Recurrence after Autologous Stem Cell Transplantation (ASCT) in Hodgkin’s Disease (HD).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only